ArticleBlood cancer journal2025
Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL.
Abstract readLetter
In one paragraph
Article in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation.Blood advances · 2026Trial
- Hodgkin lymphoma transformation in patients with chemotherapy-naïve chronic lymphocytic leukemia.Blood cancer journal · 2026Article
- Vitreoretinal lymphoma revealing Richter transformation.American journal of ophthalmology case reports · 2026Article
- Effects of chronic lymphocytic leukaemia (CLL)-directed therapy on diffuse large B-cell lymphoma (DLBCL) type Richter transformation compared to de novo DLBCL in a nationwide cohort.British journal of haematology · 2026Article
- Molecular Pathogenesis and Targeted Treatment of Richter Transformation.Biomedicines · 2026Review
- Central nervous system involvement in patients with Richter transformation of chronic lymphocytic leukemia (CLL): the Mayo Clinic experience.Blood cancer journal · 2026Article
- Richter's transformation: status quo and quo vadis.Annals of hematology · 2025Review
- Richter Transformation in Chronic Lymphocytic Leukemia: Current Treatment Challenges and Evolving Therapies.International journal of molecular sciences · 2025Review
- Disease Control and Manageable Toxicity With Epcoritamab in Refractory Diffuse Large B-Cell Lymphoma-Type Richter Syndrome: A Case Report in an Elderly Patient.Cancer reports (Hoboken, N.J.) · 2025Article
- Molecular Features Accompanying Richter's Transformation in Patients with Chronic Lymphocytic Leukemia.International journal of molecular sciences · 2025Review
- Immunotherapy in chronic lymphocytic leukemia: advances and challenges.Experimental hematology & oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
45 authors.
Adam S KittaiIcahn School of Medicine at Mount Sinai, New York, NY, USA. Adam.kittai@mssm.edu.ORCID http://orcid.org/0000-0002-4891-6144
Ying HuangDivision of Hematology, The Ohio State University, Columbus, OH, USA.
Sarah MillerDivision of Hematology, The Ohio State University, Columbus, OH, USA.
John N AllanWeill Cornell Medicine, New York, NY, USA.
Seema A BhatDivision of Hematology, The Ohio State University, Columbus, OH, USA.
David A BondDivision of Hematology, The Ohio State University, Columbus, OH, USA.
Danielle M BranderDivision of Hematologic Malignancies and Cellular Therapy, Duke University, Duke Cancer Institute, Durham, NC, USA.
John C ByrdDepartment of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA.
Julio C ChavezDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.
Elise ChongUniversity of Pennsylvania Abramson Cancer Center, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-8895-1625
Matthew S DavidsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4529-2003
Alexey V DanilovCity of Hope National Medical Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0003-4461-0970
Wei DingDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Mark R DowlingDepartment of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Australia.
Kaitlyn Dvorak-KornausDivision of Hematology, The Ohio State University, Columbus, OH, USA.
Hannah FreedmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Paul J HampelDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0003-1292-3024
Carrie HoDivision of Medical Oncology, University of Washington, Seattle, WA, USA.
Steven R HwangDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-6536-1291
Prioty IslamMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Nikita MalakhovWeill Cornell Medicine, New York, NY, USA.
Matthew MatasarDivision of Blood Disorders, Rutgers Cancer Institute, New Brunswick, NJ, USA.
Cecelia MillerDivision of Pathology, The Ohio State University, Columbus, OH, USA.
Zulfa OmerDepartment of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA.
Sameer A ParikhDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-3221-7314
Erin ParryDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Kari G RabeDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-7313-1875
Philipp W RaessDepartment of Pathology and Laboratory Medicine, Oregon Health & Science University, Portland, OR, USA.
Manoj RaiCenter for Hematologic Malignancies, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Lindsey RoekerMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-3806-059X
Joanna RhodesDivision of Blood Disorders, Rutgers Cancer Institute, New Brunswick, NJ, USA.
Kerry A RogersDivision of Hematology, The Ohio State University, Columbus, OH, USA.
Aditi SahaDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.
Jake SchadeDivision of Blood Disorders, Rutgers Cancer Institute, New Brunswick, NJ, USA.
Hamish W ScottDepartment of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Australia.
Mazyar ShadmanDivision of Medical Oncology, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-3365-6562
Geoffrey ShouseCity of Hope National Medical Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0002-7917-5713
Alan SkarbnikNovant Health Cancer Institute, Lymphoma and CLL/SLL Program, Charlotte, NC, USA.
Stephen SpurgeonCenter for Hematologic Malignancies, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Deborah M StephensLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Meghan C ThompsonMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Philip A ThompsonDepartment of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Australia.
Yucai WangDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-1576-8341
Max YanoThe Ohio State University College of Medicine, Columbus, OH, USA.
Jennifer A WoyachDivision of Hematology, The Ohio State University, Columbus, OH, USA.ORCID http://orcid.org/0000-0002-3403-9144
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTranslational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3MProteomicsP01CA206978 · NCI · DANA-FARBER CANCER INST · PI WU, CATHERINE JU-YING · 2016 to 2025
$17.0MTracing the Evolution of Chronic Lymphocytic Leukemia to Richter's Syndrome: Defining TransformationK08CA270085 · NCI · DANA-FARBER CANCER INST · PI Erin M Parry · 2022 to 2026
$945kCuring Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell LymphomasR50CA275929 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DEBORAH STEPHENS · 2023 to 2026
$673kAmerican Society of Clinical Oncology (ASCO) N/aFoundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) CA008748Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) K08CA270085Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) R50CA275929NCI NIH HHS K08 CA270085NCI NIH HHS P01 CA206978NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016058NCI NIH HHS R50 CA275929
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.